Elias Jabbour Selected Research

Drug-Related Side Effects and Adverse Reactions

6/2011	Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
3/2011	Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
10/2010	Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
6/2010	Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elias Jabbour Research Topics

Disease

130	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 05/2024 - 01/2006
117	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 05/2024 - 08/2006
103	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2023 - 03/2006
72	Philadelphia Chromosome 05/2024 - 05/2007
63	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 03/2024 - 12/2005
56	Neoplasms (Cancer) 11/2023 - 11/2004
49	Leukemia 05/2024 - 11/2005
21	Residual Neoplasm 05/2024 - 12/2013
18	Blast Crisis (Blast Phase) 01/2023 - 01/2006
13	Disease Progression 05/2024 - 06/2005
12	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2023 - 10/2006
12	Thrombocytopenia (Thrombopenia) 01/2022 - 07/2010
12	Myeloid Leukemia (Leukemia, Myelocytic) 01/2021 - 11/2006
11	Exanthema (Rash) 11/2023 - 07/2015
11	Primary Myelofibrosis (Myelosclerosis) 11/2021 - 07/2011
11	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 11/2004
10	Infections 11/2023 - 05/2012
8	Chromosome Aberrations (Chromosome Abnormalities) 01/2023 - 10/2007
7	Hypertension (High Blood Pressure) 01/2023 - 11/2015
7	Lymphoma (Lymphomas) 01/2023 - 06/2012
6	Neutropenia 04/2024 - 11/2012
6	Nausea 11/2023 - 02/2015
6	Anemia 01/2022 - 11/2013
6	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2021 - 06/2012
6	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2021 - 06/2015
6	Pathologic Complete Response 07/2020 - 05/2015
5	Acute Promyelocytic Leukemia 02/2024 - 01/2017
5	Hemorrhage 01/2023 - 07/2010
5	Fatigue 01/2021 - 03/2008
4	Myocardial Infarction 01/2023 - 10/2007
4	Pneumonia (Pneumonitis) 01/2022 - 11/2012
4	Febrile Neutropenia 01/2018 - 11/2012
4	Drug-Related Side Effects and Adverse Reactions 06/2011 - 06/2010
3	Fever (Fevers) 11/2023 - 04/2012
3	Pancreatitis 01/2023 - 11/2015
3	Cytokine Release Syndrome 12/2022 - 12/2017
3	Pleural Effusion (Pleural Effusions) 11/2022 - 01/2018
3	Hyperbilirubinemia 01/2022 - 11/2017

Drug/Important Bio-Agent (IBA)

97	Tyrosine Kinase InhibitorsIBA 05/2024 - 11/2006
67	Imatinib Mesylate (Gleevec)FDA Link 05/2024 - 01/2006
38	Dasatinib (BMS 354825)FDA Link 04/2024 - 11/2006
30	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2023 - 08/2005
28	Inotuzumab OzogamicinIBA 05/2024 - 08/2013
26	ponatinibIBA 05/2024 - 04/2015
25	Decitabine FDA Link 02/2024 - 12/2005
24	venetoclaxIBA 04/2024 - 01/2018
20	blinatumomabIBA 02/2024 - 01/2017
20	nilotinib FDA Link 01/2018 - 11/2006
19	Azacitidine (5 Azacytidine)FDA Link 11/2023 - 12/2005
15	Clofarabine (Clolar)FDA Link 01/2021 - 07/2009
15	Phosphotransferases (Kinase)IBA 06/2018 - 08/2006
13	bcr-abl Fusion ProteinsIBA 01/2022 - 07/2007
12	Vincristine (Oncovin)FDA LinkGeneric 01/2023 - 10/2010
11	Monoclonal AntibodiesIBA 01/2021 - 09/2012
10	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 11/2023 - 03/2011
9	ruxolitinibIBA 11/2021 - 08/2012
8	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2024 - 01/2009
8	Rituximab (Mabthera)FDA Link 01/2023 - 10/2010
8	Dexamethasone (Maxidex)FDA LinkGeneric 01/2023 - 10/2010
8	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2023 - 10/2010
8	Proteins (Proteins, Gene)FDA Link 01/2020 - 11/2004
7	BilirubinIBA 11/2023 - 04/2012
7	Transaminases (Aminotransferases)IBA 01/2023 - 04/2012
7	fludarabineIBA 12/2021 - 08/2010
6	fms-Like Tyrosine Kinase 3IBA 01/2022 - 11/2016
6	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021 - 10/2010
6	Core Binding Factors (Core-Binding Factor)IBA 01/2021 - 08/2010
5	Cladribine FDA LinkGeneric 11/2023 - 08/2005
5	NucleophosminIBA 01/2023 - 08/2013
5	Prednisone (Sone)FDA LinkGeneric 12/2018 - 07/2011
5	Gemtuzumab (Mylotarg)FDA Link 02/2017 - 04/2009
4	Arsenic Trioxide (Trisenox)FDA Link 02/2024 - 01/2017
4	Tretinoin (Retinoic Acid)FDA LinkGeneric 02/2024 - 01/2017
4	CreatinineIBA 01/2022 - 12/2018
4	MethyltransferasesIBA 01/2021 - 05/2011
4	Hemoglobins (Hemoglobin)IBA 01/2021 - 03/2008
4	InterferonsIBA 01/2021 - 08/2011
4	Lenalidomide (CC 5013)FDA Link 01/2021 - 07/2011
4	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 05/2011
4	guadecitabineIBA 06/2019 - 09/2015
4	Methotrexate (Mexate)FDA LinkGeneric 02/2016 - 04/2007
4	Interferon-alpha (Interferon Alfa)IBA 06/2012 - 06/2005
3	Immunoconjugates (Immunoconjugate)IBA 05/2024 - 10/2015
3	ChromatinIBA 12/2023 - 07/2023
3	Alanine Transaminase (SGPT)IBA 01/2023 - 11/2015
3	EnzymesIBA 01/2023 - 05/2012
3	Chimeric Antigen ReceptorsIBA 01/2023 - 02/2017
3	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 11/2022 - 02/2017
3	ibrutinibIBA 12/2021 - 01/2019

Therapy/Procedure

170	Therapeutics 04/2024 - 06/2005
65	Drug Therapy (Chemotherapy) 05/2024 - 02/2006
24	Stem Cell Transplantation 01/2024 - 08/2006
12	Salvage Therapy 01/2023 - 07/2009
9	Hematopoietic Stem Cell Transplantation 01/2020 - 07/2007
7	Induction Chemotherapy 01/2022 - 08/2010
6	Immunotherapy 01/2023 - 12/2016
6	Transplantation 05/2022 - 10/2007
5	Cell Transplantation 11/2022 - 10/2020
4	Consolidation Chemotherapy 12/2022 - 01/2018
3	Drug Tapering 11/2021 - 01/2018